CTI BioPharma, a commercial biopharmaceutical company focused on targeted therapies for blood-related cancers, entered into a definitive agreement under which Swedish Orphan Biovitrum AB (SOBI), a provider of hematology, immunology, and specialty care, will acquire CTI in an all-cash transaction, representing an equity value of approximately $1.7 billion. The transaction, which is expected to close in the third quarter of 2023, is also expected to diversify Sobi’s portfolio of leading h...